{"filing":{"accession_number":"0001193125-26-369674","cik":"0001776111","ticker":"MBX","company_name":"MBX Biosciences, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"mbx-20260827.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526369674/mbx-20260827.htm"},"events":[{"id":29934,"run_id":27433,"accession_number":"0001193125-26-369674","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.82,"summary":"MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for canvuparatide, a material clinical development milestone representing significant progress toward potential FDA registration of the company's lead product candidate.","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32383,"accession_number":"0001193125-26-369674","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for canvuparatide, a clinical-stage development milestone. This is a material operational/clinical event for a biopharmaceutical company advancing a drug candidate toward potential registration, but it does not fit the specific earnings_release category (no financial results disclosed) nor any other named event type. The disclosure centers on a significant clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:35:40.383903+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32384,"accession_number":"0001193125-26-369674","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"MBX Biosciences announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial for canvuparatide, a key regulatory and operational milestone for a clinical-stage biopharmaceutical company. This represents material progress toward potential FDA registration of a lead product candidate, affecting investor assessment of the company's pipeline advancement and timeline to commercialization. The event is operational/strategic rather than financial, governance, legal, or existential in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:35:40.383903+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32383,"accession_number":"0001193125-26-369674","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for canvuparatide, a clinical-stage development milestone. This is a material operational/clinical event for a biopharmaceutical company advancing a drug candidate toward potential registration, but it does not fit the specific earnings_release category (no financial results disclosed) nor any other named event type. The disclosure centers on a significant clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:35:40.383903+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-27"},{"id":32384,"accession_number":"0001193125-26-369674","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"MBX Biosciences announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial for canvuparatide, a key regulatory and operational milestone for a clinical-stage biopharmaceutical company. This represents material progress toward potential FDA registration of a lead product candidate, affecting investor assessment of the company's pipeline advancement and timeline to commercialization. The event is operational/strategic rather than financial, governance, legal, or existential in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:35:40.383903+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-27"}]}